Pamela Kirby - Hikma Pharmaceuticals Non-Executive Independent Director
HKMPY Stock | USD 46.50 0.63 1.34% |
Director
Dr. Pamela J. Kirby, Ph.D. is NonExecutive Independent Director of the Company. Dr Kirby was Chief Executive of Quintiles Transnational Corporationrationand held senior executive positions at F HoffmannLa Roche and AstraZeneca. Previously, Dr Kirby chaired Scynexis, was Senior Independent Director of Informa and held nonexecutive positions with Smith Nephew, Novo Nordisk, Curalogic, and Oscient Pharmaceuticals Corporationration Firstclass BSc degree in Pharmacology, Clinical Pharmacology PhD from the University of London. since 2014.
Age | 64 |
Tenure | 10 years |
Professional Marks | Ph.D |
Phone | 44 20 7399 2760 |
Web | https://www.hikma.com |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Elizabeth Donnelly | Marker Therapeutics | N/A | |
Arthur Sullivan | Provident Bancorp | N/A | |
Frederic MD | Immutep Ltd ADR | 69 | |
Willard Dere | Mersana Therapeutics | 64 | |
Dafna Cohen | Formula Systems 1985 | 45 | |
Eliahu Zamir | Formula Systems 1985 | 47 | |
Richard Peeke | Provident Bancorp | 69 | |
Lisa DeStefano | Provident Bancorp | N/A | |
Lawrence Alleva | Mersana Therapeutics | 67 | |
John Bosen | Provident Bancorp | 49 | |
Laurie Knapp | Provident Bancorp | 56 | |
Mark Harrison | Home Federal Bancorp | 58 | |
Kristen Hege | Mersana Therapeutics | 54 | |
Iris Yahal | Formula Systems 1985 | 53 | |
Clyde Patterson | Home Federal Bancorp | 74 | |
Pete Meyers | Immutep Ltd ADR | 46 | |
Timothy Wilhite | Home Federal Bancorp | 48 | |
Scott Lawrence | Home Federal Bancorp | 71 | |
Andres Chevallier | Betterware De Mexico | 40 | |
Rafal Kozlowski | Formula Systems 1985 | 41 | |
Grant Chamberlain | Immutep Ltd ADR | N/A |
Management Performance
Return On Equity | 0.15 | |||
Return On Asset | 0.077 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients | ||
Bassam Kanaan, Chief Strategy & Corporate Development Officer | ||
Khalid Nabilsi, Chief Officer | ||
Hussein Arkhagha, General Counsel | ||
Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
Pamela Kirby, Non-Executive Independent Director | ||
John Castellani, Non-Executive Independent Director | ||
Brian Hoffman, President and Chief Executive of - Generics Division | ||
Ali AlHusry, Non-Executive Director | ||
Jochen Gann, Non-Executive Director | ||
Engineer Darwazah, Ex CEO | ||
Peter Speirs, Company Secretary | ||
Patrick Butler, Non-Executive Independent Director | ||
Brian Hoffmann, Pres Generics | ||
Said Darwazah, Chairman and CEO | ||
Michael Raya, President and CEO, USA | ||
Samuel Park, Global US | ||
Ronald Goode, Non-Executive Independent Director | ||
Bryan Hotston, CIO | ||
Sigurdur Olafsson, CEO | ||
Breffni Byrne, Non-Executive Independent Director | ||
Nina Henderson, Non-Executive Independent Director | ||
Cynthia Schwalm, Independent Non-Executive Director | ||
Ragheb AlShakhshir, Corporate Vice President - Research & Development | ||
Michael Ashton, Non-Executive Independent Director | ||
Majda Labadi, Corporate Vice President - Human Resources | ||
Ibrahim Jalal, Sr. Corporate VP of Technical Affairs | ||
Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
Robert Pickering, Senior Non-Executive Independent Director | ||
Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | ||
CPA CFA, Exec MA |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.15 | |||
Return On Asset | 0.077 | |||
Profit Margin | 0.14 % | |||
Operating Margin | 0.22 % | |||
Current Valuation | 5.26 B | |||
Shares Outstanding | 110.13 M | |||
Price To Earning | 10.10 X | |||
Price To Book | 1.89 X | |||
Price To Sales | 1.60 X | |||
Revenue | 2.55 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hikma Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hikma Pharmaceuticals' short interest history, or implied volatility extrapolated from Hikma Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |